Takeda Pharmaceutical to Acquire Rights to Develop and Commercialize DPP4 Inhibitor from US Pharmaceutical Company Pharmaceutical Product Development.Tokyo, Japan, July 14, 2005 - (JCNN JCNN Japan Corporate News Network ) - Takeda Pharmaceutical (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). : 4502) announced on July 14 that it has agreed with Pharmaceutical Product Development (PPD (1) (Parallel Presence Detect) The method used by earlier SIMM memory modules to communicate their capacity to the computer. A binary number coming from a parallel set of pins was read by the system, with each pin representing one bit. Contrast with SPD. ), a US pharmaceutical company, concerning rights to the dipeptidyl peptidase IV (DPP DPP - Dining Philosophers Problem 4) inhibitor. Under the terms of the agreement, Takeda will be licensed to develop and commercialize the DPP inhibitor. The company will make an upfront payment of $15 million as well as development-based milestone and sales royalty payments. Further, PPD will collaborate in Phase II and III clinical trials for the DPP 4 inhibitor in the US and Europe. The DPP4 inhibitor, which is currently being developed by PPD and Takeda San Diego, a US subsidiary of Takeda, is an oral agent for the treatment of diabetes. Source: JCN http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion